WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Amir Khan's £11.5m luxury wedding venue finally hosts its first marriage: Bride arrives on horse
China issues yellow alert for blizzards
Multiple places in C.China’s Henan suspend classes, transportation due to continuous snowfall
Conference highlights human rights advancement in Xinjiang
Former senior Chongqing municipal legislator indicted for bribery
Maine is latest state to approve interstate compact for social worker licenses
LeBron James UNFOLLOWS Diddy on Instagram after video of assault on ex
China issues rules on human organ donation, transplantation
Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
Chinese cities mobilize new technologies to spur improved development